Fernando Martinez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10413233/publications.pdf

Version: 2024-02-01

38 papers 6,154 citations

411340 20 h-index 35 g-index

38 all docs

38 docs citations

38 times ranked 6690 citing authors

#	Article	IF	CITATIONS
1	Systemic Sclerosis–Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration–Approved Therapies in Clinical Practice. Arthritis and Rheumatology, 2022, 74, 13-27.	2.9	71
2	Breathing rate variability in obstructive sleep apnea during wakefulness. Journal of Clinical Sleep Medicine, 2022, 18, 825-833.	1.4	6
3	Stress in obstructive sleep apnea. Scientific Reports, 2021, 11, 12631.	1.6	16
4	Inspiratory Muscle Training for Obstructive Sleep Apnea: Protocol Development and Feasibility of Home Practice by Sedentary Adults. Frontiers in Physiology, 2021, 12, 737493.	1.3	5
5	Asthma and its relationship to mitochondrial copy number: Results from the Asthma Translational Genomics Collaborative (ATGC) of the Trans-Omics for Precision Medicine (TOPMed) program. PLoS ONE, 2020, 15, e0242364.	1.1	16
6	Impact of pre-enrolment medication use on clinical outcomes in SUMMIT. ERJ Open Research, 2019, 5, 00203-2018.	1.1	4
7	Regional differences in rate of FEV1 decline in COPD: lessons from SUMMIT. European Respiratory Journal, 2019, 53, 1900278.	3.1	2
8	The Long-Term Oxygen Treatment Trial for Chronic Obstructive Pulmonary Disease: Rationale, Design, and Lessons Learned. Annals of the American Thoracic Society, 2018, 15, 89-101.	1.5	8
9	Mucin Concentrations and Peripheral Airway Obstruction in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1453-1456.	2.5	11
10	N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still open. Lancet Respiratory Medicine,the, 2017, 5, e1-e2.	5.2	13
11	Airway Mucin Concentration as a Marker of Chronic Bronchitis. New England Journal of Medicine, 2017, 377, 911-922.	13.9	279
12	Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet, The, 2016, 387, 1817-1826.	6.3	378
13	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respiratory Medicine,the, 2016, 4, 708-719.	5.2	754
14	The Association Between Rate and Severity of Exacerbations in Chronic Obstructive Pulmonary Disease: An Application of a Joint Frailty-Logistic Model. American Journal of Epidemiology, 2016, 184, 681-689.	1.6	31
15	The cultural constructs of cancer-related fatigue among American Indian cancer survivors. Supportive Care in Cancer, 2016, 24, 1235-1240.	1.0	10
16	Preoperative Anemia, Blood Transfusion, and Neutrophil-to-Lymphocyte Ratio in Patients with Stage I Non–Small Cell Lung Cancer. Cancer Cell & Microenvironment, 2016, 3, e1116.	0.8	17
17	Shared and Unshared Barriers to Cancer Symptom Management Among Urban and Rural American Indians. Journal of Rural Health, 2014, 30, 206-213.	1.6	19
18	Genome-wide association study and admixture mapping identify different asthma-associated loci in Latinos: The Genes-environments & Latinos: The Genes-environments & Latino Americans study. Journal of Allergy and Clinical Immunology, 2014, 134, 295-305.	1.5	106

#	Article	IF	CITATIONS
19	Prediction of Acute Respiratory Disease in Current and Former Smokers With and Without COPD. Chest, 2014, 146, 941-950.	0.4	71
20	Pulmonary Hypertension Due to Left Heart Diseases. Journal of the American College of Cardiology, 2013, 62, D100-D108.	1.2	541
21	Factors to Inform Clinicians About the End of Life in Severe Chronic Obstructive Pulmonary Disease. Journal of Pain and Symptom Management, 2013, 46, 491-499.e4.	0.6	30
22	Severe Chronic Bronchitis in Advanced Emphysema Increases Mortality and Hospitalizations. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2013, 10, 667-678.	0.7	27
23	"Weaving Balance into Life― Development and cultural adaptation of a cancer symptom management toolkit for Southwest American Indians. Journal of Cancer Survivorship, 2012, 6, 182-188.	1.5	25
24	BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 92-99.	2.5	497
25	The Effect of Lung Volume Reduction Surgery on Chronic Obstructive Pulmonary Disease Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 164-169.	2.5	95
26	Role of macrolide therapy in chronic obstructive pulmonary disease. International Journal of COPD, 2008, Volume 3, 331-350.	0.9	99
27	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Chest, 2007, 132, 1652-1658.	0.4	159
28	Management of infants with chronic lung disease of prematurity in Chile. Early Human Development, 2005, 81, 143-149.	0.8	10
29	Clinical Implications of Macrolide Therapy in Chronic Sinopulmonary Diseases. Current Pharmaceutical Design, 2004, 10, 3095-3110.	0.9	16
30	A Randomized Trial Comparing Lung-Volume–Reduction Surgery with Medical Therapy for Severe Emphysema. New England Journal of Medicine, 2003, 348, 2059-2073.	13.9	1,842
31	Statement on the Care of the Child with Chronic Lung Disease of Infancy and Childhood. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 356-396.	2.5	305
32	Role of Physiological Assessment in Usual Interstitial Pneumonia. Lung Biology in Health and Disease, 2003, , 137-166.	0.1	0
33	Role of High-Resolution Thin Section Computed Tomographic Scanning. Lung Biology in Health and Disease, 2003, , 167-236.	0.1	0
34	Nonspecific Interstitial Pneumonia. Lung Biology in Health and Disease, 2003, , 101-136.	0.1	0
35	Patients at High Risk of Death after Lung-Volume–Reduction Surgery. New England Journal of Medicine, 2001, 345, 1075-1083.	13.9	612
36	Usual Interstitial Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2001, 22, 357-386.	0.8	34

#	Article	IF	CITATIONS
37	Surgical Therapy for Chronic Obstructive Pulmonary Disease: Conventional Bullectomy and Lung Volume Reduction Surgery in the Absence of Giant Bullae. Seminars in Respiratory and Critical Care Medicine, 1999, 20, 351-364.	0.8	8
38	Lung Volume Reduction Surgery Alters Management of Pulmonary Nodules in Patients With Severe COPD. Chest, 1997, 112, 1494-1500.	0.4	37